Related Article: COPD Exacerbation Treatment.
COPD Medications available in the United States
Table of Contents
Anticholinergics
Short-acting anticholinergics
- Ipratropium (Atrovent).Two sprays four times per day (MDI).
Long-acting anticholinergics
- Tiotropium (Spiriva). One puff per day (DPI).
- Aclidinium bromide (Tudorza Pressair). One puff two times per day (DPI)
Side effects for all anticholinergics are the same: “Anaphylaxis, angle-closure glaucoma, hypersensitivity reaction, paradoxical bronchospasm”
Beta-agonists
Short-acting beta-agonists
- Albuterol 2 to 4 mg orally, BID to TID. Albuterol comes as MDI & DPI, solution for a nebulizer, oral pills of 2, 4, 5, mg or ER tab of 8 mg. Also comes as syrup.
- Levalbuterol (Xopenex) as a nebulizer. 0.63 to 1.25 mg q6-8h PRN (nebulizer)
- Terbutaline
Long-acting beta-agonists
- Arformoterol (Brovana). One vial two times per day (nebulizer)
- Formoterol. One puff two times per day (DPI)
- Indacaterol (Arcapta Neohaler). One puff per day (DPI)
- Salmeterol (Serevent). One puff every 12 hours (DPI)
- Olodaterol
Combination Short-acting anticholinergic and short-acting beta2 agonist
- Ipratropium / Albuterol (Duoneb)
Combination Long-acting anticholinergic and long-acting beta2 agonist
- Tiotropium / Olodaterol (Stiolto Respimat). Two puffs per day (MDI)
- Umeclidinium/Vilanterol (Anoro Ellipta). One puff per day (DPI)
Combination corticosteroid and long-acting beta2 agonist
- Budesonide/formoterol (Symbicort). Two puffs two times per day (MDI)
- Fluticasone/salmeterol (Advair Diskus). One puff every 12 hours (DPI)
- Fluticasone/vilanterol (Breo Ellipta). One puff per day (DPI)
Phosphodiesterase-4 inhibitor
- Roflumilast (Daliresp) 500 mcg orally, once per day
Methylxanthine
- Theophylline, extended release. 300 to 600 mg orally per day, in one or two doses
DPI = dry powder inhaler; MDI = metered dose inhaler
References
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report, Pocket Guide, Page 15.
Am Fam Physician. 2017 Apr 1;95(7):433-441. https://www.aafp.org/afp/2017/0401/p433.html